In the context of engaged international competition, it is necessary to track developments in the field of genomic medicine at international level, to be able to anticipate the necessary adjustments and changes of direction, in the context of the implementation of the plan and to ensure an optimal quality of service to patients, while maintaining the competitiveness of the national players of the developed industrial sector.

Lire la suite

OÙ EN EST-ON ?

Signature of Memorandum of Understanding for the French-British strategic Genomics Research and Development Partnership with Genomics England. - septembre 2018

This agreement will enable the two parties to develop a normative framework which will ensure that both countries adopt the new technologies appropriately while advancing at an optimal pace;

Via Inserm, Aviesan, is a member of the International Consortium for personalised medicine, ICPerMed - septembre 2016
Lire la suite

ICPerMed was launched at workshops organised by the European Commission.

It includes non-profit public and private bodies for funding health research and the setting up of public policies. ICPerMed wants to contribute to the implementation of personalised medicine for the benefit of patients, citizens and society as a whole and to facilitate the coordination of research and financing activities, first at European level then at international level. The FPGM 2025 takes part in working groups dedicated to “health economics, regulation and market access” aspects and “data and information and communication technology”;

At international level, the FPGM 2025 is currently working on the implementation of collaboration agreements with the initiatives: Genome British Columbia in Canada; Genome Quebec; inter alia. - septembre 2016
Discussions on the participation in the European initiative “Towards access to 1 million Genomes in the EU by 2022” - septembre 2016

In which representatives of member States are invited to co-sign a common declaration indicating political support for the pooling of current and future genomic data banks (on a voluntary basis) in order to reach a cohort of 1 million sequenced genomes accessible in the European Union by 2022.

SUR CE THÈME
Communiqué de presse
Articles
Vidéos